ERS Genomics licenses CRISPR tech to DefiniGEN

ERS Genomics Ltd. (Dublin, Ireland) granted DefiniGEN Ltd. (Cambridge, U.K.) non-exclusive rights to CRISPR-Cas9 IP that will be combined with DefiniGEN's induced pluripotent stem cell (iPSC) platform to create CRISPR-edited preclinical human disease models.

DefiniGEN plans to use the technology to develop cell models of metabolic disease, including rare liver diseases, Type II diabetes and non-alcoholic fatty liver disease (NAFLD)...